Pancreatitis, Chronic Clinical Trial
Official title:
Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis
The research objective of this pilot study is to test the feasibility of a mobile electronic
mindfulness therapy service for patients with definite or suspected chronic pancreatitis.
A secondary aim will be to determine the effect of the intervention on a symptom
severity/global assessment of improvement for patients with chronic pancreatitis. The
investigators hypothesize that a one-month period of daily mindfulness therapy delivered via
a phone messaging service will reduce symptoms.
Patients who meet diagnostic criteria for definite or suspected chronic pancreatitis and
have current symptoms over the past month will be considered for study enrollment. Potential
patients will be initially pre-screened by a patient chart review.
If not excluded during the pre-screening process, potential subjects will be mailed
questionnaires to fill out at home and speak with a member of the research team for an
intake interview. At that time, they will be asked to sign a consent form after its review.
Subjects will then be given instructions on how to participate in daily mindfulness therapy
for one-month via the phone messaging service with a research team member.
The total duration of the study intervention will be four weeks where enrolled patients will
be asked to perform daily mindfulness sessions through our electronic mobile mindfulness
therapy service.
Patients will be sent a daily automated text message or call reminder to their mobile phone
at a pre-determined time, selected by the patient at the intake interview. The text message
will prompt patients with a phone number to call to access the Mindfulness Therapy sessions.
When the patient is ready, s/he will call the provided phone number which is an automated
answering and voice messaging service, which will prompt the patient to select a mindfulness
therapy session of varying durations from 2 to 30 minutes. The session will lead the
patients through deep relaxation breathing exercise for the duration the patient selected
from the phone menu. Although the investigators will only ask patients to do one mindfulness
session a day, patients are free to do as many as they want a day. At the end of their
session, patients will leave a voice message with their name and current location such as
home or work. The investigators will track the mindfulness sessions the individual patient
participated in by obtaining their recorded voice messages in an inbox that correlates with
the duration of the mindfulness session that the patient participated in. The voice
messaging system will also provide information of the time the voice message was left, or
time of completion of the patient's mindfulness session. If the patient prematurely
terminated his/her session, got disconnected from his/her session or forgot to leave a
message, the patient may call the same provided phone number to leave a message with his/her
name, date of unrecorded session along with its duration and location of participation such
as home or work.
At the end of the study at four weeks, patients will be asked to complete an exit interview.
The patient will be asked to fill out questionnaires during this interview. The patient will
also be asked to participate in an informal exit interview with one of the research team
members. Patients will be asked of any new medications were added during the duration of the
study. They will also be asked regarding any changes in chronic pancreatitis strategies and
any new stressors.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05326542 -
Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP
|
N/A | |
Completed |
NCT01551511 -
Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain
|
Phase 2 | |
Completed |
NCT01731821 -
Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
|
Phase 3 | |
Active, not recruiting |
NCT05095831 -
EUS Shear Wave for Solid Pancreatic Lesions.
|
||
Completed |
NCT03173118 -
Elastography in the Diagnosis of Chronic Pancreatitis
|
N/A | |
Terminated |
NCT01318590 -
Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis
|
Phase 3 | |
Recruiting |
NCT05772234 -
Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis
|
N/A | |
Recruiting |
NCT04131010 -
Digital Catheter Based Pancreatoscopy (SpyGlassDS) for the Management of Symptomatic Pancreatic Duct Stones in Selected Patients With Chronic Pancreatitis
|
N/A | |
Terminated |
NCT00359320 -
A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT02940067 -
Enhancing Fitness Before Pancreatic Surgery
|
N/A | |
Recruiting |
NCT05261997 -
Endotherapy for Painless Chronic Pancreatitis
|
N/A | |
Not yet recruiting |
NCT05270434 -
Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.
|
N/A | |
Completed |
NCT03672422 -
Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
|
||
Enrolling by invitation |
NCT05287737 -
Clinical Outcome After Total Pancreatectomy With Islet Autotransplantation
|
||
Not yet recruiting |
NCT06426160 -
Tocilizumab for Painful Chronic Pancreatitis
|
Phase 2 | |
Enrolling by invitation |
NCT05289362 -
Comparison of Efficacy of Basket and Balloon in the Removal of Pancreatic Duct Stones in Chronic Pancreatitis Under ERCP
|
N/A | |
Not yet recruiting |
NCT04760847 -
Intermittent Fasting for Pancreatitis
|
N/A | |
Enrolling by invitation |
NCT03228095 -
Volatiles in Breath and Headspace Analysis - Diagnostic Markers
|
||
Completed |
NCT00956839 -
Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis
|
Phase 4 | |
Completed |
NCT00676702 -
A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)
|
Phase 1 |